Cefpodoxime pharmacokinetics in children: effect of food.
BACKGROUND
Cefpodoxime, an oral third generation cephalosporin antibiotic, is used for the treatment of acute upper respiratory tract infection caused by susceptible bacteria in children 5 months to 12 years of age. We report the results of a randomized two-way crossover study designed to characterize the disposition of a single dose (10 mg/kg) of cefpodoxime proxetil oral suspension in children, under fed and fasted conditions.


METHODS
Seventeen children (8.4 months to 12.2 years old, seven female) participated in this study. Each subject received a single 10-mg/kg dose of cefpodoxime proxetil oral suspension, after a predose fast and again coadministered with food. Repeated blood samples (n=10) were obtained during 12 h postdose and cefpodoxime was quantified from plasma by high performance liquid chromatography. Plasma concentration vs. time data were curve fit for each subject with a nonlinear weighted least squares algorithm, and pharmacokinetic parameters were determined from the polyexponential estimates.


RESULTS
Cefpodoxime disposition was best characterized using a one-compartment open model with first order absorption. The area under the plasma concentration vs. time curve, Cmax and Ke were not significantly different between fed and fasted conditions. However, Tmax was significantly prolonged (fed=2.79+/-1.10 h vs. fasted=1.93+/-0.54 h) and Ka was significantly smaller (fed=0.42+/-0.14 h(-1) vs. fasted=0.81+/-0.72 h(-1)) in the fed state.


CONCLUSIONS
Administration of cefpodoxime in the presence of food affected the rate but not the extent of absorption. Cefpodoxime proxetil oral suspension can be administered without regard to meals in children 6 months to 12 years of age.
Section of Pediatric Clinical Pharmacology and Experimental Therapeutics, The Children's Mercy Hospital, Kansas City, MO 64108, USA. gkearns@cmh.edu
G L
GL
Kearns
S M
SM
Abdel-Rahman
R F
RF
Jacobs
T G
TG
Wells
M T
MT
Borin
D019540:Area Under Curve; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D002511:Cephalosporins / Q000097:blood / Q000493:pharmacokinetics*; D002648:Child; D002675:Child, Preschool; D018592:Cross-Over Studies; D004435:Eating; D005215:Fasting; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011355:Prodrugs / Q000493:pharmacokinetics*; D000097627:Cefpodoxime Proxetil
D015296:Ceftizoxime; D002511:Cephalosporins; D011355:Prodrugs; D000097627:Cefpodoxime Proxetil